Protalix BioTherapeutics EBITDA 2010-2024 | PLX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Protalix BioTherapeutics ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Protalix BioTherapeutics ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.9B
Amgen (AMGN)	$158.1B
Gilead Sciences (GILD)	$134.2B
Vertex Pharmaceuticals (VRTX)	$121.1B
Bristol Myers Squibb (BMY)	$111.6B
CSL (CSLLY)	$80.7B
GSK (GSK)	$75.7B
Regeneron Pharmaceuticals (REGN)	$75B
Argenex SE (ARGX)	$38.9B
Alnylam Pharmaceuticals (ALNY)	$32.4B
BioNTech SE (BNTX)	$28.7B
BeiGene (ONC)	$23.2B
Biogen (BIIB)	$20B
Illumina (ILMN)	$16.3B
Insmed (INSM)	$15B
Genmab (GMAB)	$14.5B
Genmab (GNMSF)	$14.4B
Moderna (MRNA)	$13.8B
Intra-Cellular Therapies (ITCI)	$13.7B
Incyte (INCY)	$13.6B
BioMarin Pharmaceutical (BMRN)	$12.5B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Bio-Techne Corp (TECH)	$10.4B
Vaxcyte (PCVX)	$10.4B
Sarepta Therapeutics (SRPT)	$10.2B
Exelixis (EXEL)	$9.8B
Ascendis Pharma (ASND)	$9.4B
Exact Sciences (EXAS)	$9.3B
Bio-Rad Laboratories (BIO.B)	$8.7B
QIAGEN (QGEN)	$8.7B